The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
Open accessAbstract
Hepatitis C virus (HCV) infects ∼2% of the world's population. It is estimated that there are more than 500,000 new infections annually in Egypt, the country with the highest HCV prevalence. An effective vaccine would help control this expanding global health burden. HCV is highly variable, and an effective vaccine should target conserved T- and B-cell epitopes of the virus. Conserved B-cell epitopes overlapping the CD81 receptor-binding site (CD81bs) on the E2 viral envelope glycoprotein have been reported previously and provide promising vaccine targets. In this study, we isolated 73 human mAbs recognizing five distinct antigenic regions on the virus envelope glycoprotein complex E1E2 from an HCV-immune phage-display antibody library by using an exhaustive-panning strategy. Many of these mAbs were broadly neutralizing. In particular, the mAb AR4A, recognizing a discontinuous epitope outside the CD81bs on the E1E2 complex, has an exceptionally broad neutralizing activity toward diverse HCV genotypes and protects against heterologous HCV challenge in a small animal model. The mAb panel will be useful for the design and development of vaccine candidates to elicit broadly neutralizing antibodies to HCV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.-G., Mizokami, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1268 · Cited by 2,754
Complete Replication of Hepatitis C Virus in Cell Culture
Lindenbach, B. D., Evans, M. J., Syder, A. J., Wölk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., et al. (2005) · Science · doi:10.1126/science.1114016 · Cited by 2,238
Self-citationHepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citationRobust hepatitis C virus infection in vitro
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T., & Chisari, F. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503596102 · Cited by 1,709
Self-citationInfectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes
Bartosch, B., Dubuisson, J., & Cosset, F.-L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021756 · Cited by 1,111
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C. M., & McKeating, J. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0832180100 · Cited by 795
Self-citationAntibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637
Self-citationter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S. W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 612
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
Law, M., Maruyama, T., Lewis, J., Giang, E., Tarr, A. W., Stamataki, Z., Gastaminza, P., Chisari, F. V., Jones, I. M., Fox, R. I., et al. (2008) · Nature Medicine · doi:10.1038/nm1698 · Cited by 591
Self-citationDubuisson, J., Hsu, H. H., Cheung, R. C., Greenberg, H. B., Russell, D. G., & Rice, C. M. (1994) · Journal of Virology · doi:10.1128/jvi.68.10.6147-6160.1994 · Cited by 425
Self-citationA genetically humanized mouse model for hepatitis C virus infection
Dorner, M., Horwitz, J. A., Robbins, J. B., Barry, W. T., Feng, Q., Mu, K., Jones, C. T., Schoggins, J. W., Catanese, M. T., Burton, D. R., et al. (2011) · Nature · doi:10.1038/nature10168 · Cited by 378
Self-citationFlying Under the Radar: The Immunobiology of Hepatitis C
Dustin, L. B., & Rice, C. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141602 · Cited by 313
Self-citationOwsianka, A., Tarr, A. W., Juttla, V. S., Lavillette, D., Bartosch, B., Cosset, F.-L., Ball, J. K., & Patel, A. H. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11095-11104.2005 · Cited by 289
Lavillette, D., Tarr, A. W., Voisset, C., Donot, P., Bartosch, B., Bain, C., Patel, A. H., Dubuisson, J., Ball, J. K., & Cosset, F. (2005) · Hepatology · doi:10.1002/hep.20542 · Cited by 271
Krey, T., d'Alayer, J., Kikuti, C. M., Saulnier, A., Damier-Piolle, L., Petitpas, I., Johansson, D. X., Tawar, R. G., Baron, B., Robert, B., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000762 · Cited by 248
Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt
Miller, F. D., & Abu-Raddad, L. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008877107 · Cited by 203
Scheel, T. K. H., Gottwein, J. M., Jensen, T. B., Prentoe, J. C., Hoegh, A. M., Alter, H. J., Eugen-Olsen, J., & Bukh, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711044105 · Cited by 194
Self-citationAntibody-mediated neutralization of flaviviruses: A reductionist view
Dowd, K. A., & Pierson, T. C. (2011) · Virology · doi:10.1016/j.virol.2010.12.020 · Cited by 186
Meunier, J.-C., Russell, R. S., Goossens, V., Priem, S., Walter, H., Depla, E., Union, A., Faulk, K. N., Bukh, J., Emerson, S. U., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01872-07 · Cited by 178
Self-citationStructure-based antigen design: a strategy for next generation vaccines
Dormitzer, P. R., Ulmer, J. B., & Rappuoli, R. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.08.002 · Cited by 169
Nomenclature and Numbering of the Hepatitis C Virus
KUIKEN, C. L., & Peter Simmonds, K. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-394-3_4 · Cited by 159
Zhang, P. C., Zhong, L., Struble, E. B., Watanabe, H., Kachko, A. V., Mihalik, K., Virata, M. L., Alter, H. J., Feinstone, S. M., & Major, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902749106 · Cited by 145
Meunier, J., Fournillier, A., Choukhi, A., Cahour, A., Cocquerel, L., Dubuisson, J., & Wychowski, C. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-4-887 · Cited by 135
Safran, M., Kim, W. Y., Kung, A. L., Horner, J. W., Depinho, R. A., & Kaelin, W. G. (2003) · Molecular Imaging · doi:10.1162/153535003322750637 · Cited by 134
Sabo, M. C., Luca, V. C., Prentoe, J. C., Hopcraft, S. E., Blight, K. J., Yi, M., Lemon, S. M., Ball, J., Bukh, J., Evans, M. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00586-11 · Cited by 122
Self-citationSong, L., Sun, Z.-Y. J., Coleman, K. E., Zwick, M. B., Gach, J. S., Wang, J., Reinherz, E. L., Wagner, G., & Kim, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901474106 · Cited by 107
Blocking Hepatitis C Virus Infection with Recombinant Form of Envelope Protein 2 Ectodomain
Whidby, J., Mateu, G., Scarborough, H. A., Demeler, B., Grakoui, A., & Marcotrigiano, J. (2009) · Journal of Virology · doi:10.1128/jvi.00800-09 · Cited by 62
Antibodies against viruses: passive and active immunization
Law, M., & Hangartner, L. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.005 · Cited by 56
Self-citationProgressive epitope-blocked panning of a phage library for isolation of human RSV antibodies
Tsui, P., Tornetta, M. A., Ames, R. S., Silverman, C., Porter, T. G., Weston, C. Q., Griego, S. D., & Sweet, R. W. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00032-7 · Cited by 12
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Webster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Burton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1225416 · Cited by 415
Self-citation
Metadata
- Authors
- Giang, E., Dorner, M., Prentoe, J. C., Dreux, M., Evans, M. J., Bukh, J., Rice, C. M., Ploss, A., Burton, D. R., & Law, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-04-04
- Volume
- 109
- Issue
- 16
- Pages
- 6205-6210
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2102253058
- Cited by
- 346
- References
- 33
- FWCI
- 18.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.